Hydralazine
هیدرالازین
❤️ Cardiovascular SystemVasodilator
Market / country: 🇺🇸 USA
Apresoline (US)
🧮 Dose calculator
Hypertension · Regimen source: FDA Hydralazine · Dosage and Administration
- • Days 2–4: 10 mg qid; rest of week 1: 25 mg qid; from week 2: 50 mg qid. Occasionally up to 300 mg/day. FDA Hydralazine · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity; coronary artery disease; mitral valvular rheumatic heart disease. FDA Hydralazine · Contraindications
- ⛔ Injection: hypersensitivity; coronary artery disease; rheumatic mitral valve disease. FDA Hydralazine inj. · Contraindications
Formulations
- 10 mg tablet — tablet 🇺🇸 USA FDA Hydralazine · How Supplied
- 25 mg tablet — tablet 🇺🇸 USA FDA Hydralazine · How Supplied
- 50 mg tablet — tablet 🇺🇸 USA FDA Hydralazine · How Supplied
- 100 mg tablet — tablet 🇺🇸 USA FDA Hydralazine · How Supplied
- 20 mg/mL injection (1 mL vial) — injection 🇺🇸 USA FDA Hydralazine inj. · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Hydralazine · Pregnancy
“Teratogenic Effects Pregnancy Category C Animal studies indicate that hydrALAZINE is teratogenic in mice at 20 to 30 times the maximum daily human dose of 200 to 300 mg and possibly in rabbits at 10 to 15 times the maximum daily human dose, but that it is nonteratogenic in rats.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Hydralazine · Nursing Mothers
“HydrALAZINE has been shown to be excreted in breast milk.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Hydralazine · Pediatric Use
“Safety and effectiveness in pediatric patients have not been established in controlled clinical trials, although there is experience with the use of hydrALAZINE in pediatric patients.”
- 👴 Older adultsNo data
The source for this drug has no section for this group.
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA200770
- DailyMed (FDA label)FDA HydralazineFDA Hydralazine inj.
- MedlinePlus (NIH)Hydralazine
- WHO ATC/DDDC02DB02
- Darooyab (Iran)Hydralazine
🇮🇷 Registered in Iran Darooyab · G-1705/Hydralazine
Dosage forms with Iranian generic codes, per Darooyab.
- 00631 · HYDRALAZINE HCL 10MG TAB · قرص هیدرالازین هیدروکلراید ۱۰ میلیگرم
- 00632 · HYDRALAZINE HCL 20MG/ML AMP · آمپول هیدرالازین هیدروکلراید ۲۰ میلیگرم / میلیلیتر
- 11435 · HYDRALAZINE HCL 25MG AMP · آمپول هیدرالازین هیدروکلراید ۲۵ میلیگرم
- 00633 · HYDRALAZINE HCL 25MG TAB · قرص هیدرالازین هیدروکلراید ۲۵ میلیگرم
- 00634 · HYDRALAZINE HCL 50MG TAB · قرص هیدرالازین هیدروکلراید ۵۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Hydralazine · How SuppliedFDA Hydralazine inj. · How SuppliedFDA Hydralazine · Dosage and AdministrationFDA Hydralazine · Pediatric UseFDA Hydralazine inj. · Dosage and AdministrationFDA Hydralazine · ContraindicationsFDA Hydralazine inj. · ContraindicationsFDA Hydralazine · PregnancyFDA Hydralazine · Nursing MothersFDA Hydralazine · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1705/Hydralazine
- Clinical review⚠ Unverified